Enzyme within cancer cells prevents immune system from fighting disease
An enzyme in cancer cells called aconitate decarboxylase (Acod1) appears to cause the release of short chains of amino acids, called peptides, that interfere with the way our bodies’ immune cells fight the disease, a new study by University of Notre Dame cancer biologist Zachary Schafer shows.
According to a research article in Cell Reports, cancer cells with high levels of Acod1, located in the mitochondria — the “powerhouses” of cells — were discovered to decrease the effectiveness of a certain type of cancer therapy called immune checkpoint inhibitor therapy. These drugs block protein “checkpoints” made by our immune system’s T cells and some cancer cells, preventing the T cells from killing the cancer. This type of cancer immunotherapy has proven to be effective in some cancers like melanomas, but not for cancers including prostate cancer, according to Schafer, the Coleman Foundation Associate Professor of Cancer Biology in the Department of Biological Sciences.
Previous research on Acod1, including another recent study in the lab of Xin Lu, the John M. and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences, has been focused on how Acod1 impacts the behavior and function of immune cells themselves.
“Our research shows that the cancer cells can use this enzyme as well. Surprisingly, Acod1 activity in cancer cells dampens the immune response, which is a really novel and exciting discovery,” said Schafer, who is affiliated with the Harper Cancer Research Institute.
![James H. Schofield and Zachary T. Schafer](https://science.nd.edu/assets/569173/schafer_schofield_5_15_2024.jpg)
As part of the experiments described in Schafer’s paper, researchers reduced the levels of Acod1 inside of prostate cancer cells. Next, the researchers introduced those altered cells into mouse models. Once the levels of Acod1 in the cancer cells were reduced, the immune checkpoint inhibitor therapy worked: The T cells rushed in to do their job, diminishing the cancer.
This project grew out of research in Schafer’s lab from 2018, when his group discovered a novel cancer cell death pathway involving changes in the mitochondria. Following that paper, his lab discovered that the cancer cells that were defective in this cell death pathway were also resistant to immune checkpoint inhibitors. He and collaborators then determined that, as a result of the significant changes in the mitochondria, Acod1 was responsible for the resistance to immune checkpoint inhibitors.
“That the cancer cells are better able to evade the immune response is totally dependent on this Acod1 enzyme,” Schafer said. “It’s definitely antagonizing the effect of the T-cells.”
Schafer and members of his lab are continuing to explore the effects of Acod1 for future studies. For instance, Schafer is interested in how Acod1 causes the production of the peptides, and he does not yet know the precise configuration of the amino acids in the peptides released by cancer cells with Acod1.
“We do not yet know how the T cells interact with these peptides, which is the other thing is that we are trying to figure out,” Schafer said.
This study was led by recent Notre Dame Ph.D. graduate James H. Schofield. In addition to Schafer and Schofield, other authors on the study are Emma Albano, Mark A. Hawk, Sean Murphy, Loan Duong, Sharif Rahmy,and Xin Lu, all from the University of Notre Dame, as well as Abigail E. Ellis, Joseph Longo, Russell G. Jones and Ryan D. Shelton of the Van Andel Institute, Grand Rapids, Michigan.
The paper was funded by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the Coleman Foundation, and the Malanga Family Excellence Fund for Cancer Research, and the College of Science and Department of Biological Sciences at Notre Dame.
Originally published by science.nd.edu on May 16, 2024.
atLatest Research
- Notre Dame marks another year of unprecedented research successDuring the 2024 fiscal year, researchers at the University of Notre Dame submitted 1,310 proposals for external research funding for a total amount of $1.016 billion — the first time the University has surpassed the billion-dollar mark for proposals. In addition, the University received 829 separate awards — the largest number on record. With $223 million in total funding, these awards propelled the University past the $200 million mark for the fourth straight year.
- Chile provides fruitful opportunities for collaboration and researchAll over the world, Notre Dame faculty are carrying out research and making exciting discoveries. For most, their work would not be possible if not for partnerships with global universities, programs, and individuals. One such example is the research produced by Yamil J. Colón-Rodríguez, Ph.D., assistant…
- Notre Dame startups Grannus Therapeutics and TayCo Brace gain recognition and opportunities at Rally pitch competitionElevate Ventures' second annual Rally IN-Prize pitch contest, held on August 27 and 28 in Indianapolis, is touted as one of the world’s largest startup investment pitch competitions, offering up to $1 million in investment financing…
- Research Project Outcomes: Driving inclusive urban growth through community-centric AI auditsSingapore has established itself as a global leader in smart city development, known for its innovative use of advanced technology and dedication to forward-thinking practices. As a "Smart City Index champion," the city-state consistently ranks at the top of the IMD…
- Mary McAleese: Politics of the Sacred and the Necessity for Respectful DiscourseMary McAleese served as the eighth president of Ireland from 1997 to 2011 and serves as the current President of the Advisory Board for the Ansari Institute for Global Engagement with Religion. …
- Notre Dame partners to grow Indiana’s mental health workforceThe University of Notre Dame is part of a statewide effort to address the mental health workforce shortage. In partnership with WISE Indiana, the University is contracted to help enhance the recruitment, retention and quality of Indiana’s behavioral health workforce.